- Home
- ENR vs ETNB Comparison
ENR vs ETNB Comparison
Compare ENR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENR
- ETNB
- Stock Information
- Founded
- ENR 2015
- ETNB 2018
- Country
- ENR United States
- ETNB United States
- Employees
- ENR N/A
- ETNB N/A
- Industry
- ENR Industrial Machinery/Components
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ENR Miscellaneous
- ETNB Health Care
- Exchange
- ENR Nasdaq
- ETNB Nasdaq
- Market Cap
- ENR 1.6B
- ETNB 1.5B
- IPO Year
- ENR N/A
- ETNB 2019
- Fundamental
- Price
- ENR $29.01
- ETNB $8.61
- Analyst Decision
- ENR Hold
- ETNB Strong Buy
- Analyst Count
- ENR 7
- ETNB 10
- Target Price
- ENR $31.43
- ETNB $27.22
- AVG Volume (30 Days)
- ENR 717.7K
- ETNB 1.4M
- Earning Date
- ENR 08-04-2025
- ETNB 11-06-2025
- Dividend Yield
- ENR 4.10%
- ETNB N/A
- EPS Growth
- ENR 2300.45
- ETNB N/A
- EPS
- ENR 3.41
- ETNB N/A
- Revenue
- ENR $2,925,600,000.00
- ETNB N/A
- Revenue This Year
- ENR $3.12
- ETNB N/A
- Revenue Next Year
- ENR $2.92
- ETNB N/A
- P/E Ratio
- ENR $8.57
- ETNB N/A
- Revenue Growth
- ENR 1.15
- ETNB N/A
- 52 Week Low
- ENR $19.70
- ETNB $4.16
- 52 Week High
- ENR $39.52
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ENR 60.81
- ETNB 41.28
- Support Level
- ENR $28.12
- ETNB $8.33
- Resistance Level
- ENR $29.41
- ETNB $9.47
- Average True Range (ATR)
- ENR 0.64
- ETNB 0.42
- MACD
- ENR -0.08
- ETNB -0.04
- Stochastic Oscillator
- ENR 84.13
- ETNB 21.71
About ENR Energizer Holdings Inc.
Energizer Holdings Inc makes and distributes household batteries, specialty batteries, and lighting products. Energizer offers batteries using lithium, alkaline, carbon-zinc, nickel-metal hydride, zinc-air, and silver oxide technologies. These products are sold under the Energizer, Rayovac, Varta and Eveready brands at performance and premium price segments. It also offers auto care products in the appearance, fragrance, performance, and air conditioning recharge product categories. The company operates in two geographical segments: Americas and International, of which the majority of its revenue is derived from the America. It has two product segments: Batteries & Lights and Auto Care. It earns maximum revenue from Batteries & Lights segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).